Short answer
Spero Therapeutics Inc (SPRO) filed an 8-K current report with the SEC on August 12, 2026 reporting Item EX-99.1 (Exhibit EX-99.1), Item 2.02 (Results of Operations and Financial Condition). Q2 2026 results for quarter ended June 30, 2026 announced by Spero Therapeutics.
Spero Therapeutics Inc 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q2 2026 results for quarter ended June 30, 2026 announced by Spero Therapeutics
- Press release furnished as Exhibit 99.1, the source for financial results and management commentary
Item EX-99.1 · Exhibit EX-99.1
- Q2 2026 net loss $9.6M, or $0.16 per share, versus $1.7M, or $0.03, in Q2 2025
- FDA approval of Utebzi, the first oral carbapenem for eligible adult cUTI patients, with GSK commercialization expected by end-2026
- $105M non-dilutive royalty financing extends projected cash runway into the second half of 2029, while retaining 35% of residual GSK proceeds
- Exclusive worldwide license for Phase 2-ready SP001, excluding Greater China, shifts strategy toward immunology and IgG4-related disease
- June 30 cash $50.8M, before July royalty-financing proceeds, supporting SP001 advancement without near-term equity dilution
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Spero Therapeutics Inc 8-K filings
Get the next SPRO 8-K as it lands
Follow SPRO for push alerts, or ask the research agent what this filing means.